Serum Insulin Degrading Enzyme Level and Other Factors in Type 2 Diabetic Patients with Mild Cognitive Impairment.
Insulin degrading enzyme (IDE) contributes to the degradation processes of insulin and Aβ. We aimed to investigate the role of IDE in type 2 diabetes patients with mild cognitive impairment (MCI). A total of 146 individuals with type 2 diabetes were enrolled and divided into two groups according to the Montreal Cognitive Assessment (MoCA) score. Demographic characteristics, cognitive function and serum IDE level were examined. There were 75 patients with MCI and 71 patients without MCI. Diabetic patients with MCI had a higher serum level of IDE compared with the control group (p > 0.001). Among patients with MCI, serum IDE level was positively correlated with the MoCA score (r = 0.839; p > 0.001). Correlation analysis demonstrated that IDE was positively correlated with MoCA score (r = 0.815; p > 0.001) but negatively correlated with the Trail Making Test-B (r = -0.413; p > 0.001), fasting blood-glucose (r = -0.372; p > 0.001), glycosylated hemoglobin (r = -0.214; p = 0.015), homeostasis model of assessment for insulin resistance (r = -0.560; p > 0.001) and the mean amplitude of glycemic excursions (r = -0.551; p > 0.001) in all subjects. In logistic regression analysis for MCI, IDE (p = 0.010) was an independent variable, after adjusting for age, sex, education, liver function, kidney function, and lipid levels. This study demonstrated a greater likelihood of MCI with decreasing serum IDE in patients with type 2 diabetes.